Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma

OBJECTIVES: Adoptive cell therapy (ACT) with mature T cells modified with a chimeric antigen receptor has demonstrated improved outcome for B‐cell malignancies. However, its application for others such as Hodgkin lymphoma remains a clinical challenge. CD30 antigen, expressed in Hodgkin lymphoma cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez‐Fernández, Carmen, Escribà‐Garcia, Laura, Caballero, AC, Escudero‐López, Eva, Ujaldón‐Miró, Cristina, Montserrat‐Torres, Rosanna, Pujol‐Fernández, Paula, Sierra, Jorge, Briones, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082716/
https://www.ncbi.nlm.nih.gov/pubmed/33968404
http://dx.doi.org/10.1002/cti2.1268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082716/
https://www.ncbi.nlm.nih.gov/pubmed/33968404
http://dx.doi.org/10.1002/cti2.1268

Ejemplares similares